Recent Updates — RPRX

Royalty Pharma reported third-quarter 2026 financial results, announcing a 9% increase in Royalty Receipts to $883 million and Portfolio Receipts to $890 million. The company raised its full-year 2026 guidance for Portfolio Receipts to between $3.5 billion and $3.55 billion, up from the previous range of $3.4 billion to $3.5 billion. Net cash provided by operating activities was $686 million, while Adjusted EBITDA reached $840 million. Royalty Pharma also disclosed the acquisition of royalties on Zoryve and Mimrylo for $100 million each, bringing total announced transaction value to $1.9 billion year-to-date. The company operates in the biopharmaceutical industry as a leading buyer of royalties and funder of innovation.

Royalty Pharma plc reported second quarter 2026 financial results and raised full-year guidance for Portfolio Receipts to $3,400 million–$3,500 million. Royalty Receipts grew 14% to $768 million, driven by Tremfya, Voranigo, Imdelltra, and Evrysdi, while total Portfolio Receipts increased 6% to $773 million. The company paid a quarterly dividend of $0.235 per share in the quarter and repurchased approximately 0.9 million shares for $45 million. Royalty Pharma acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, bringing total Capital Deployment to over $1 billion in 2026. The company operates in the life sciences sector as a premier buyer of biopharmaceutical royalties and funder of innovation.